Skip to main content
SpringerLink
Log in

Deferiprone cost saving for iron overload in thalassaemia

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2014 euros

Reference

  • Pepe A, et al. A Cost-Utility Analysis of Deferiprone Compared to Desferrioxamine and Deferasirox for the Treatment of Chronic Myocardial Iron Overload in Thalassemia Patients. 57th Annual Meeting and Exposition of the American Society of Hematology : abstr. 2077, 5 Dec 2015. Available from: URL: https://ash.confex.com/ash/2015/webprogram/Paper81179.html

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Deferiprone cost saving for iron overload in thalassaemia. PharmacoEcon Outcomes News 745, 14 (2016). https://doi.org/10.1007/s40274-016-2755-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-2755-4

Search

Navigation